• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

I/II期非小细胞肺癌患者胸腔镜切除术后合并症负担与生存差异

Survival Differences by Comorbidity Burden among Patients with Stage I/II Non-Small-Cell Lung Cancer after Thoracoscopic Resection.

作者信息

Wheeler Meghann, Karanth Shama D, Mehta Hiren J, Yang Danting, Aduse-Poku Livingstone, Washington Caretia, Hong Young-Rock, Zhang Dongyu, Gould Michael K, Braithwaite Dejana

机构信息

Department of Epidemiology, University of Florida College of Public Health and Health Professions, Gainesville, FL 32603, USA.

University of Florida Health Cancer Center, Gainesville, FL 32603, USA.

出版信息

Cancers (Basel). 2023 Mar 30;15(7):2075. doi: 10.3390/cancers15072075.

DOI:10.3390/cancers15072075
PMID:37046735
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10093192/
Abstract

We sought to compare overall survival (OS) by comorbidity burden among patients with stage I/II non-small cell lung cancer (NSCLC) who received thoracoscopic resection. Utilizing data from the National Cancer Database, we conducted a survival analysis among patients aged 50+ with stage I/II NSCLC who received thoracoscopic resection between 2010 and 2017. The comorbidity burden was measured by the Charlson comorbidity index (CCI, 0, 1, 2+). Multivariable Cox proportional hazard models were used to compare overall survival relative to the CCI (CCI of 0 as the referent). Subgroup analyses were conducted considering sex, age groups, days from diagnosis to surgery, facility type, laterality, and type of surgery. For this study, 61,760 patients were included, with a mean age of 69.1 years (SD: 8.5). Notably, 51.2% had a CCI of 0, 31.8% had a CCI of 1, and 17.0% had a CCI of 2+. Most participants were non-Hispanic White (87.5%), and 56.9% were female. We found that an increase in the CCI was associated with a higher risk of all-cause mortality (CCI 1 vs. 0 aHR: 1.24, 95% CI: 1.20-1.28; CCI 2+ vs. 0 aHR: 1.51, 95% CI: 1.45-1.57; p-trend < 0.01). Our subgroup analysis according to sex suggested that the association between CCI and risk of death was stronger in women.

摘要

我们试图比较接受胸腔镜切除术的Ⅰ/Ⅱ期非小细胞肺癌(NSCLC)患者中,不同合并症负担情况下的总生存期(OS)。利用国家癌症数据库的数据,我们对2010年至2017年间年龄在50岁及以上、接受胸腔镜切除术的Ⅰ/Ⅱ期NSCLC患者进行了生存分析。合并症负担通过Charlson合并症指数(CCI,0、1、2+)来衡量。使用多变量Cox比例风险模型比较相对于CCI(以CCI为0作为参照)的总生存期。根据性别、年龄组、从诊断到手术的天数、医疗机构类型、手术侧别和手术类型进行亚组分析。本研究纳入了61760例患者,平均年龄为69.1岁(标准差:8.5)。值得注意的是,51.2%的患者CCI为0,31.8%的患者CCI为1,17.0%的患者CCI为2+。大多数参与者为非西班牙裔白人(87.5%),56.9%为女性。我们发现,CCI升高与全因死亡率风险增加相关(CCI 1与0相比,调整后风险比[aHR]:1.24,95%置信区间[CI]:1.20 - 1.28;CCI 2+与0相比,aHR:1.51,95% CI:1.45 - 1.57;P趋势<0.01)。我们根据性别的亚组分析表明,CCI与死亡风险之间的关联在女性中更强。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fac8/10093192/d86d6b559a82/cancers-15-02075-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fac8/10093192/79071b546946/cancers-15-02075-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fac8/10093192/d86d6b559a82/cancers-15-02075-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fac8/10093192/79071b546946/cancers-15-02075-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fac8/10093192/d86d6b559a82/cancers-15-02075-g002.jpg

相似文献

1
Survival Differences by Comorbidity Burden among Patients with Stage I/II Non-Small-Cell Lung Cancer after Thoracoscopic Resection.I/II期非小细胞肺癌患者胸腔镜切除术后合并症负担与生存差异
Cancers (Basel). 2023 Mar 30;15(7):2075. doi: 10.3390/cancers15072075.
2
Impact of comorbidity burden on morbidity following thoracoscopic lobectomy: a propensity-matched analysis.合并症负担对胸腔镜肺叶切除术后发病率的影响:一项倾向匹配分析。
J Thorac Dis. 2018 Mar;10(3):1806-1814. doi: 10.21037/jtd.2018.02.62.
3
Effect of comorbidities on long-term outcomes after thoracoscopic surgery for stage I non-small cell lung cancer patients with chronic obstructive pulmonary disease.合并症对患有慢性阻塞性肺疾病的I期非小细胞肺癌患者胸腔镜手术后长期预后的影响。
J Thorac Dis. 2018 Feb;10(2):909-919. doi: 10.21037/jtd.2018.01.57.
4
Impact of Comorbidity Scores on the Overall Survival of Patients With Advanced Non-small Cell Lung Cancer: A Real-World Experience From Eastern India.合并症评分对晚期非小细胞肺癌患者总生存的影响:来自印度东部的真实世界经验
Cureus. 2022 Oct 22;14(10):e30589. doi: 10.7759/cureus.30589. eCollection 2022 Oct.
5
Comorbidity Assessment Using Charlson Comorbidity Index and Simplified Comorbidity Score and Its Association With Clinical Outcomes During First-Line Chemotherapy for Lung Cancer.使用查尔森合并症指数和简化合并症评分进行合并症评估及其与肺癌一线化疗期间临床结局的关联
Clin Lung Cancer. 2016 May;17(3):205-213.e1. doi: 10.1016/j.cllc.2015.10.002. Epub 2015 Oct 22.
6
Usefulness of Charlson Comorbidity Index to Predict Early Mortality and Overall Survival in Older Patients With Acute Myeloid Leukemia.Charlson 合并症指数在预测老年急性髓系白血病患者早期死亡率和总生存率中的作用。
Clin Lymphoma Myeloma Leuk. 2020 Dec;20(12):804-812.e8. doi: 10.1016/j.clml.2020.07.002. Epub 2020 Jul 6.
7
Comparison of Charlson comorbidity index and Kaplan-Feinstein index in patients with stage I lung cancer after surgical resection.手术切除后I期肺癌患者的Charlson合并症指数与Kaplan-Feinstein指数比较
Eur J Cardiothorac Surg. 2007 Dec;32(6):877-81. doi: 10.1016/j.ejcts.2007.09.008. Epub 2007 Oct 17.
8
Risk factors for postoperative complications after lung resection for non-small cell lung cancer in elderly patients at a single institution in China.中国某单一机构老年非小细胞肺癌患者肺切除术后并发症的危险因素。
J Thorac Dis. 2014 Sep;6(9):1230-8. doi: 10.3978/j.issn.2072-1439.2014.07.23.
9
Association of the Charlson comorbidity index and hypertension with survival in men with metastatic castration-resistant prostate cancer.合并 Charlson 共病指数和高血压与转移性去势抵抗性前列腺癌男性患者生存的关系。
Urol Oncol. 2014 Jan;32(1):36.e27-34. doi: 10.1016/j.urolonc.2013.02.015. Epub 2013 May 16.
10
Comorbidities and Charlson score in resected stage I nonsmall cell lung cancer.I期非小细胞肺癌切除术后的合并症及查尔森评分
Eur Respir J. 2005 Sep;26(3):480-6. doi: 10.1183/09031936.05.00146004.

引用本文的文献

1
Creating Opportunities to Eliminate Disparities in Lung Cancer Outcomes: A Call for Diverse Study Populations. Comment on Kohan et al. Disparity and Diversity in NSCLC Imaging and Genomics: Evaluation of a Mature, Multicenter Database. 2023, , 2096.创造消除肺癌治疗结果差异的机会:呼吁开展多样化研究人群的研究。对科汉等人的评论。非小细胞肺癌影像学与基因组学中的差异与多样性:对一个成熟的多中心数据库的评估。2023年,,2096。 (注:原文中部分逗号处信息缺失,译文按原样呈现)
Cancers (Basel). 2023 Jul 25;15(15):3762. doi: 10.3390/cancers15153762.

本文引用的文献

1
Frailty and risk of mortality in older cancer survivors and adults without a cancer history: Evidence from the National Health and Nutrition Examination Survey, 1999-2014.衰弱与老年癌症幸存者和无癌症病史成年人的死亡率风险:来自 1999-2014 年全国健康和营养调查的证据。
Cancer. 2022 Aug 1;128(15):2978-2987. doi: 10.1002/cncr.34258. Epub 2022 May 24.
2
Cancer statistics, 2022.癌症统计数据,2022 年。
CA Cancer J Clin. 2022 Jan;72(1):7-33. doi: 10.3322/caac.21708. Epub 2022 Jan 12.
3
Survival of Black and White Patients With Stage IV Small Cell Lung Cancer.
IV期小细胞肺癌黑人和白人患者的生存率。
Front Oncol. 2021 Dec 10;11:773958. doi: 10.3389/fonc.2021.773958. eCollection 2021.
4
The Impact of Persistent Smoking After Surgery on Long-term Outcomes After Stage I Non-small Cell Lung Cancer Resection.I期非小细胞肺癌切除术后持续吸烟对长期预后的影响。
Chest. 2022 Jun;161(6):1687-1696. doi: 10.1016/j.chest.2021.12.634. Epub 2021 Dec 14.
5
Sex-differences in symptoms and functioning in >5000 cancer survivors: Results from the PROFILES registry.超过 5000 名癌症幸存者的症状和功能的性别差异:来自 PROFILES 登记处的结果。
Eur J Cancer. 2021 Oct;156:24-34. doi: 10.1016/j.ejca.2021.07.019. Epub 2021 Aug 16.
6
Cardiovascular Complications Associated with Contemporary Lung Cancer Treatments.与当代肺癌治疗相关的心血管并发症。
Curr Treat Options Oncol. 2021 Jun 10;22(8):71. doi: 10.1007/s11864-021-00869-6.
7
NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 2.2021.NCCN 指南解读:非小细胞肺癌,第 2.2021 版。
J Natl Compr Canc Netw. 2021 Mar 2;19(3):254-266. doi: 10.6004/jnccn.2021.0013.
8
Factors Associated With Health-Related Quality of Life Among Cancer Survivors in the United States.美国癌症生存者健康相关生活质量的影响因素
JNCI Cancer Spectr. 2021 Jan 23;5(1). doi: 10.1093/jncics/pkaa123. eCollection 2021 Feb.
9
Uptake and survival effects of minimally invasive surgery for lung cancer: A population-based study.微创肺癌手术的摄取和生存效果:基于人群的研究。
Eur J Surg Oncol. 2021 Jul;47(7):1791-1796. doi: 10.1016/j.ejso.2021.01.002. Epub 2021 Jan 13.
10
Long-term survival of thoracoscopic surgery compared with open surgery for clinical N0 adenocarcinoma.与开胸手术相比,胸腔镜手术治疗临床N0期腺癌的长期生存率。
J Thorac Dis. 2020 Nov;12(11):6523-6532. doi: 10.21037/jtd-20-2259.